Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
14 mars 2023 16h05 HE
|
Design Therapeutics, Inc.
Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Ongoing with Data Expected Mid-Year Continued Progress Across Pipeline of GeneTAC™ Small Molecules with Three Programs Expected...
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
08 févr. 2023 06h30 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
07 déc. 2022 16h01 HE
|
Design Therapeutics, Inc.
DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment...
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
03 nov. 2022 16h05 HE
|
Design Therapeutics, Inc.
Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multiple-Ascending Dose Phase 1 Trial of DT-216;...
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
17 oct. 2022 16h05 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
22 sept. 2022 06h30 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
08 août 2022 16h05 HE
|
Design Therapeutics, Inc.
Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022 Strong Financial Position with $359.4 Million in Cash and Securities to Support Multi-Year Operating...
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
03 août 2022 06h30 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
01 juin 2022 06h30 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
09 mai 2022 16h05 HE
|
Design Therapeutics, Inc.
Clinical Execution of Lead GeneTAC™ Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia Robust Research Pipeline of GeneTAC™ Candidates, with Promising New...